FDA advises against using compounded remdesivir products
![FDA-guidance](/sites/default/files/styles/900x400/public/2018-07/FDA-guidance.jpg?itok=I8jaZmAO)
The Food and Drug Administration yesterday cautioned health care providers against using compounded remdesivir drug products due to the potential for patient exposure to substandard or adulterated products.
“Because it is challenging to formulate remdesivir as a stable drug, the agency is concerned that compounded remdesivir drug products could be of low quality potentially resulting in patient harm,” the agency said. “Furthermore, heightened interest in remdesivir due to its use in COVID-19 patients may increase the risk that a substandard or counterfeit [active pharmaceutical ingredient] is sold to compounders.”
Related News Articles
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…